ArticleJournal of proteome research2012
Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: implications in molecular imaging.
Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 63 citations in OpenAlex.
- Pharmacological intervention of Chinese medicine via regulating ferroptosis in gastric cancer.Chinese medicine · 2026Review
- A Diimidazole-Based Amphiphilic Probe for Wash-Free Cell Plasma Membrane Imaging.Journal of fluorescence · 2025Article
- Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.Molecular metabolism · 2024Review
- Remodeling of the gastric environment inmSystems · 2024Article
- Pattern discovery of long non-coding RNAs associated with the herbal treatments in breast and prostate cancers.Quantitative biology (Beijing, China) · 2023Article
- Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance.Frontiers in oncology · 2023Review
- Identification and analysis of a prognostic ferroptosis and iron-metabolism signature for esophageal squamous cell carcinoma.Journal of Cancer · 2022Article
- LncRNA SNHG6 Silencing Could Arrest Progression of High Grade Colorectal Cancers.Iranian journal of pathology · 2022Article
- A panel of urine-derived biomarkers to identify sepsis and distinguish it from systemic inflammatory response syndrome.Scientific reports · 2021Article
- Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics.Clinical pharmacology and therapeutics · 2021Article
- Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients.Drug delivery · 2020Article
- An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes.Frontiers in oncology · 2020Review
- Biased Influences of Low Tumor Purity on Mutation Detection in Cancer.Frontiers in molecular biosciences · 2020Article
- Effect of haptoglobin on the treatment of chronic hepatitis B with interferon.Experimental and therapeutic medicine · 2019Article
- The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring.Cells · 2018Review
- The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.British journal of cancer · 2018Article
- Proteomic investigation of the effects of preimplantation factor on human embryo implantation.Molecular medicine reports · 2018Article
- Nondestructive Analysis of Tumor-Associated Membrane Protein Integrating Imaging and Amplified Detection in situ Based on Dual-Labeled DNAzyme.Theranostics · 2018Article
- SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer.Oncotarget · 2017Article
- iTRAQ-based quantitative proteomic analysis of Yamanaka factors reprogrammed breast cancer cells.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite decreasing incidence and mortality, gastric cancer remains the second leading cause of cancer-related deaths in the world. Successful management of gastric cancer is hampered by lack of highly sensitive and specific biomarkers especially for early cancer detection. Cell surface proteins that are aberrantly expressed between normal and cancer cells are potentially useful for cancer imaging and therapy due to easy accessibility of these targets. Combining two-phase partition and isobaric tags for relative and absolute quantification methods, we compared the relative expression levels of membrane proteins between noncancer and gastric cancer cells. About 33% of the data set was found to be plasma membrane and associated proteins using this approach (compared to only 11% in whole cell analysis), several of which have never been previously implicated in gastric cancer. Upregulation of SLC3A2 in gastric cancer cells was validated by immunoblotting of a panel of 13 gastric cancer cell lines and immunohistochemistry on tissue microarrays comprising 85 matched pairs of normal and tumor tissues. Immunofluorescence and immunohistochemistry both confirmed the plasma membrane localization of SLC3A2 in gastric cancer cells. The data supported the notion that SLC3A2 is a potential biomarker that could be exploited for molecular imaging-based detection of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.